ES2526816B1 - Compositions for the treatment of liver damage - Google Patents

Compositions for the treatment of liver damage Download PDF

Info

Publication number
ES2526816B1
ES2526816B1 ES201330895A ES201330895A ES2526816B1 ES 2526816 B1 ES2526816 B1 ES 2526816B1 ES 201330895 A ES201330895 A ES 201330895A ES 201330895 A ES201330895 A ES 201330895A ES 2526816 B1 ES2526816 B1 ES 2526816B1
Authority
ES
Spain
Prior art keywords
liver damage
compositions
treatment
stimulate
survival
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES201330895A
Other languages
Spanish (es)
Other versions
ES2526816A1 (en
Inventor
Yolanda ALMADÉN PEÑA
Carmen HERENCIA BELLIDO
Juan Rafael MUÑOZ CASTAÑEDA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
FUNDACION PARA LA INVESTIGACION BIOMEDICA DE CORDOBA
Universidad de Cordoba
Fundacion Publica Andaluza Progreso y Salud
Original Assignee
FUNDACION PARA LA INVESTIGACION BIOMEDICA DE CORDOBA
Universidad de Cordoba
Fundacion Publica Andaluza Progreso y Salud
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by FUNDACION PARA LA INVESTIGACION BIOMEDICA DE CORDOBA, Universidad de Cordoba, Fundacion Publica Andaluza Progreso y Salud filed Critical FUNDACION PARA LA INVESTIGACION BIOMEDICA DE CORDOBA
Priority to ES201330895A priority Critical patent/ES2526816B1/en
Priority to PCT/ES2014/070497 priority patent/WO2014198996A1/en
Publication of ES2526816A1 publication Critical patent/ES2526816A1/en
Application granted granted Critical
Publication of ES2526816B1 publication Critical patent/ES2526816B1/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • E—FIXED CONSTRUCTIONS
    • E06—DOORS, WINDOWS, SHUTTERS, OR ROLLER BLINDS IN GENERAL; LADDERS
    • E06B—FIXED OR MOVABLE CLOSURES FOR OPENINGS IN BUILDINGS, VEHICLES, FENCES OR LIKE ENCLOSURES IN GENERAL, e.g. DOORS, WINDOWS, BLINDS, GATES
    • E06B9/00—Screening or protective devices for wall or similar openings, with or without operating or securing mechanisms; Closures of similar construction
    • E06B9/02—Shutters, movable grilles, or other safety closing devices, e.g. against burglary
    • E06B9/08—Roll-type closures
    • E06B9/11—Roller shutters
    • E06B9/17—Parts or details of roller shutters, e.g. suspension devices, shutter boxes, wicket doors, ventilation openings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Structural Engineering (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Architecture (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Civil Engineering (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Composiciones para el tratamiento del daño hepático.#La presente invención describe el uso del contenido intracelular de células madre mesenquimales en individuos con daño hepático agudo para estimular la supervivencia, regeneración y/o reparación del órgano dañado. Además, la presente invención también describe el uso de este lisado para la elaboración de una composición farmacéutica que comprenda dicho contenido intracelular, destinada a estimular la supervivencia, regeneración y/o reparación de órganos, específicamente del hígado.Compositions for the treatment of liver damage. # The present invention describes the use of intracellular content of mesenchymal stem cells in individuals with acute liver damage to stimulate the survival, regeneration and / or repair of the damaged organ. In addition, the present invention also describes the use of this lysate for the preparation of a pharmaceutical composition comprising said intracellular content, intended to stimulate the survival, regeneration and / or repair of organs, specifically of the liver.

Description

imagen1image 1

imagen2image2

imagen3image3

imagen4image4

imagen5image5

imagen6image6

imagen7image7

imagen8image8

imagen9image9

imagen10image10

imagen11image11

imagen12image12

imagen13image13

imagen14image14

imagen15image15

imagen16image16

imagen17image17

imagen18image18

imagen19image19

imagen20image20

imagen21image21

imagen22image22

imagen23image23

imagen24image24

imagen25image25

Claims (1)

imagen1image 1
ES201330895A 2013-06-14 2013-06-14 Compositions for the treatment of liver damage Expired - Fee Related ES2526816B1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
ES201330895A ES2526816B1 (en) 2013-06-14 2013-06-14 Compositions for the treatment of liver damage
PCT/ES2014/070497 WO2014198996A1 (en) 2013-06-14 2014-06-16 Compositions for the treatment of liver damage

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES201330895A ES2526816B1 (en) 2013-06-14 2013-06-14 Compositions for the treatment of liver damage

Publications (2)

Publication Number Publication Date
ES2526816A1 ES2526816A1 (en) 2015-01-15
ES2526816B1 true ES2526816B1 (en) 2015-10-27

Family

ID=51033224

Family Applications (1)

Application Number Title Priority Date Filing Date
ES201330895A Expired - Fee Related ES2526816B1 (en) 2013-06-14 2013-06-14 Compositions for the treatment of liver damage

Country Status (2)

Country Link
ES (1) ES2526816B1 (en)
WO (1) WO2014198996A1 (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2578081T3 (en) * 2006-10-11 2016-06-27 Massachusetts Gen Hospital Compositions, methods and devices for the treatment of liver disease
ES2423483T3 (en) * 2007-10-29 2013-09-20 Fresenius Medical Care Deutschland Gmbh Use of microvesicles (MV) derived from stem cells to prepare a drug for endothelial / epithelial regeneration of damaged or damaged tissues or organs, and related methods in vitro and in vivo

Also Published As

Publication number Publication date
WO2014198996A1 (en) 2014-12-18
ES2526816A1 (en) 2015-01-15

Similar Documents

Publication Publication Date Title
ES2582284T3 (en) Composition comprising anaerobically cultured human intestinal microbiota
ES2540751T3 (en) Composition to improve male sexual function that contains ginseng berry extract
ES2496092T3 (en) The use of amisulpride to treat postoperative nausea and vomiting
SV2017005461A (en) BENZAMIDS REPLACED WITH 1,3-TIAZOL-2-ILO
CL2015001984A1 (en) (divisional sol. 1567-2013) combinations of active ingredients comprising pyridylethylbenzamides and other active ingredients.
CL2014001865A1 (en) Phosphate derived compounds; preparation procedure; pharmaceutical compositions containing them and use in the treatment of cancer.
ES2508165T3 (en) Lactoferrin and white matter
ECSP17015154A (en) METHODS TO IMPROVE MYOCARDIAL PERFORMANCE IN PATIENTS WITH FONTAN SURGERY USING UDENAFILO COMPOSITIONS
NI201500175A (en) NEW COMPOUNDS FOR THE TREATMENT OF CANCER
NI201500078A (en) COMPOSITIONS INCLUDING VORTIOXETINE AND DONEPEZILO.
BR112013014189A2 (en) pharmaceutical composition comprising transcinamaldehyde and its use in the treatment of infections
CL2016001546A1 (en) Composition for oral care comprising serine and at least one zinc salt.
ES2629309T3 (en) Formulations of treatment of mucositis induced by antitumor or immunosuppressive therapy
CL2012003265A1 (en) Tamarind seed polysaccharide for use in the treatment of infectious diseases; pharmaceutical and / or anti-inflammatory dermocosmetic composition containing said polysaccharide; use of a tamarind seed polysaccharide.
CL2015000537A1 (en) Siarn and its use in methods and compositions for the treatment and / or prevention of eye diseases.
CL2015002191A1 (en) Topical antifungal composition for the treatment of onychomycosis.
CL2014000792A1 (en) Composition for use in the promotion of magnesium absorption and / or magnesium retention
ES2598753T3 (en) Pharmaceutical composition for the treatment of calcified tendinitis and / or calcified bursitis
CR20160369A (en) COMPOSITIONS FOR USE IN THE TREATMENT OF ALLERGIC AFFECTIONS
CU20180110A7 (en) A COMPOSITION THAT INCLUDES PIC FOR TREATMENT OF CANCER
ES2526816B1 (en) Compositions for the treatment of liver damage
AR085399A1 (en) ANTITUMORAL COMBINATION INCLUDING CABAZITAXEL AND CISPLATINO
ES2550461T3 (en) Use of S-adenosylmethionine (SAM) and superoxide dismutase (SOD) for the preparation of medicinal products for the treatment of Alzheimer's disease
ES2536842T3 (en) Pharmaceutical composition for cancer treatment
ES2446494B1 (en) Therapeutic application of necrostatin-1 in steatohepatitis

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 2526816

Country of ref document: ES

Kind code of ref document: B1

Effective date: 20151027

FD2A Announcement of lapse in spain

Effective date: 20211202